A Phase 4 interventional study of tramadol hydrochloride + acetaminophen in Arthritis, Rheumatoid, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2010-11-30.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Arthritis, Rheumatoid by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Johnson & Johnson.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 21st largest by enrollment of the 75 interventional ones that give a count, is one of 18 in phase 4, and was the 12th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson is open now, in 1 country. Recruiting first, the newest first:
DePuy Orthopaedics · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 210 across the 75 interventional studies, 370 across the 15 observational. Of the 86 that completed or were terminated, 31 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Korea, Ltd., Korea, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness of ULTRACET® (a combination analgesic) as add-on therapy in rheumatoid arthritis patients taking an NSAID (e.g. Advil®, Motrin® or other nonsteroidal anti-inflammatory drug) or a COX-2 inhibitor (e.g. Celebrex®).
This is a randomized, multicenter, placebo-controlled, double-blind study to evaluate the efficacy and safety of ULTRACET® (tramadol 37.5 mg and acetaminophen 325 mg) as add-on therapy in rheumatoid arthritis patients taking an NSAID or a COX-2 inhibitor. The patients will be randomized into 2 treatment groups: The first group will receive one ULTRACET® tablet 3 times per day for 7 days. The second group will receive one placebo tablet 3 times per day for 7 days. The primary efficacy measurement will be the patients' average daily pain score. Safety will be monitored throughout the study. The study hypothesis is that ULTRACET® will be well tolerated and the average daily pain relief score for the ULTRACET® treatment group will be better than that of placebo group. Patients will take one ULTRACET® tablet or placebo by mouth 3 times per day, for 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Tramadol · Acetaminophen
Average daily pain relief score
Average daily pain intensity score; average pain relief and intensity score for the final visit; patient's assessment of physical function; overall assessment by the patient; overall assessment by the investigator; and an evaluation of safety
No study locations are listed for this record.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen